141 related articles for article (PubMed ID: 27394672)
1. How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis?
Busquets-Pérez N; Ponce A; Ortiz-Santamaria V; de Agustín de Oro J; Hernández-Rico YL; Vidal I; Alfonso C; Argemí S; Muñoz B; Quispe F; Díaz AC; Campos S; Hernández TM; Torres M; Surís X
Reumatol Clin; 2017; 13(5):282-286. PubMed ID: 27394672
[TBL] [Abstract][Full Text] [Related]
2. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
3. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
4. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
Ringrose JS; Sanche SE; Taylor-Gjevre RM
Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
[TBL] [Abstract][Full Text] [Related]
5. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
[TBL] [Abstract][Full Text] [Related]
8. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
9. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
10. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
11. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
[TBL] [Abstract][Full Text] [Related]
12. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Balbir-Gurman A; Lidgi M; Elkayam O
Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha antagonist therapy modify the tuberculin skin test response.
Cagatay T; Kilicaslan Z; Cagatay P; Mertsoylu M; Gulbaran Z; Yildiz R; Pur L; Kamali S; Gul A
Rheumatol Int; 2011 Sep; 31(9):1147-51. PubMed ID: 20349071
[TBL] [Abstract][Full Text] [Related]
14. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
[TBL] [Abstract][Full Text] [Related]
15. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
[TBL] [Abstract][Full Text] [Related]
16. ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.
Girlanda S; Mantegani P; Baldissera E; Aiello P; Ratti M; Sabbadini MG; Fortis C
Clin Rheumatol; 2010 Oct; 29(10):1135-41. PubMed ID: 20645117
[TBL] [Abstract][Full Text] [Related]
17. [Screening for tuberculosis before TNFα treatment in routine rheumatic care in Iceland. Result from the nationwide ICEBIO registry].
Bjorgulfsson TM; Gröndal G; Blondal T; Gudbjornsson B
Laeknabladid; 2018 Mai; 104(5):231-235. PubMed ID: 29717989
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the prevalence of latent tuberculosis infection in patients with moderate to severe plaque psoriasis in Spain: The Latent study.
Ribera M; Zulaica A; Pujol C; Alonso ML; Rodriguez IM; Garcia-Calvo C;
Actas Dermosifiliogr; 2015 Dec; 106(10):823-9. PubMed ID: 26381434
[TBL] [Abstract][Full Text] [Related]
19. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Sánchez-Moya AI; Dauden E
J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
[TBL] [Abstract][Full Text] [Related]
20. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
